Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Zong‐Hao Duan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0728-5972; OpenAlex author ID A5059893675, A5102375353. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers · 2024: 5 papers · 2025: 2 papers · 2026: 2 papers

Papers 12

  1. A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing… Co-author DOI 10.1158/1078-0432.ccr-25-3359↗
  2. OSBPL10 Drives Lipophagy-Mediated Lipid Mobilization to Promote Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.7150/ijbs.125552↗
  3. Vitamin K-dependent gamma-carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosin… Co-author DOI 10.1002/ctm2.70191↗
  4. TMEM105 modulates disulfidptosis and tumor growth in pancreatic cancer via the β-catenin-c-MYC-GLUT1 axis. Co-author DOI 10.7150/ijbs.104598↗
  5. AGFG1 increases cholesterol biosynthesis by disrupting intracellular cholesterol homeostasis to promote PDAC progression. Co-author DOI 10.1016/j.canlet.2024.217130↗
  6. A CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2024.114633↗
  7. OCIAD2 promotes pancreatic cancer progression through the AKT signaling pathway. Co-author DOI 10.1016/j.gene.2024.148735↗
  8. Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-024-07110-w↗
  9. The lncRNA LINC01605 promotes the progression of pancreatic ductal adenocarcinoma by activating the mTOR signaling pathway. Co-author DOI 10.1186/s12935-024-03440-z↗
  10. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Co-author DOI 10.1007/s13402-022-00741-1↗
  11. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-CXCR4 … Co-author DOI 10.1007/s13402-023-00791-z↗
  12. Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/ph15111336↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Sun · 9 shared papers, 2022–2026 · strength 1.71
  2. Yan‐Miao Huo · 8 shared papers, 2023–2026 · strength 1.61
  3. Qin-Yuan Jia · 8 shared papers, 2022–2025 · strength 1.45
  4. Hong‐Fei Yao · 7 shared papers, 2022–2025 · strength 1.27
  5. Jia-Hao Zheng · 7 shared papers, 2023–2024 · strength 1.26
  6. Yu-Heng Zhu · 6 shared papers, 2022–2025 · strength 1.10
  7. Minwei Yang · 5 shared papers, 2024–2026 · strength 1.07
  8. Linli Yao · 4 shared papers, 2023–2026 · strength 0.80
  9. Jian‐Yu Yang · 4 shared papers, 2022–2026 · strength 0.76
  10. Shu‐Heng Jiang · 4 shared papers, 2023–2025 · strength 0.74
  11. Yifan Yin · 4 shared papers, 2024 · strength 0.73
  12. Wei Liu · 3 shared papers, 2024–2026 · strength 0.59
  13. Dejun Liu · 3 shared papers, 2024–2025 · strength 0.56
  14. Dejun Liu · 3 shared papers, 2022–2024 · strength 0.49
  15. Yifan Yin · 2 shared papers, 2024–2025 · strength 0.40
  16. Rong Hua · 2 shared papers, 2024 · strength 0.36
  17. Li-Peng Hu · 2 shared papers, 2024 · strength 0.35
  18. Jian Yang · 2 shared papers, 2022–2024 · strength 0.31
  19. Pei‐Xuan Ji · 2 shared papers, 2022–2024 · strength 0.31
  20. Hong Li · 1 shared paper, 2026 · strength 0.26
  21. Yingbin Liu · 1 shared paper, 2026 · strength 0.26
  22. Junfeng Zhang · 1 shared paper, 2026 · strength 0.26
  23. Wei Liu · 1 shared paper, 2025 · strength 0.22
  24. Dong‐Xue Li · 1 shared paper, 2025 · strength 0.21
  25. Zheng Wu · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.